Synonyms: | |
Status: | Phase 3 |
Entry Type: | Small molecule |
Molecule Category: | UNKNOWN |
UNII: | GPO2JN4UON |
InChI Key | JHDKZFFAIZKUCU-ZRDIBKRKSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C20H30N4O2 |
Molecular Weight | 358.49 |
AlogP | 3.24 |
Hydrogen Bond Acceptor | 5.0 |
Hydrogen Bond Donor | 2.0 |
Number of Rotational Bond | 10.0 |
Polar Surface Area | 70.39 |
Molecular species | BASE |
Aromatic Rings | 2.0 |
Heavy Atoms | 26.0 |
Primary Target | |
---|---|
histone deacetylase 10 |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class I
|
- | 140-2835 | - | 16-27 | 93 | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIa
|
- | 126 | - | 107 | 93 | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | 82-3162 | - | 23 | 93 | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IV
|
- | 126 | - | 43 | 93 | |
Unclassified protein
|
- | 70 | - | - | - |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Leukemia, Myeloid, Acute | 3 | D015470 | ClinicalTrials |
Myelodysplastic Syndromes | 2 | D009190 | ClinicalTrials |
Sarcoma | 2 | D012509 | ClinicalTrials |
Myeloproliferative Disorders | 2 | D009196 | ClinicalTrials |
Prostatic Neoplasms, Castration-Resistant | 2 | D064129 | ClinicalTrials |
Leukemia | 1 | D007938 | ClinicalTrials |
Neoplasms | 1 | D009369 | ClinicalTrials |
Neoplasms | 1 | D009369 | ClinicalTrials |
Resources | Reference |
---|---|
ChEBI | 95071 |
ChEMBL | CHEMBL1851943 |
DrugBank | DB05223 |
EPA CompTox | DTXSID00239196 |
FDA SRS | GPO2JN4UON |
Guide to Pharmacology | 8365 |
PubChem | 49855250 |
SureChEMBL | SCHEMBL833105 |
ZINC | ZINC000043152558 |